The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.

Provided are solid dispersions of Compound I having the formula:

##STR00001##

wherein Compound I is substantially amorphous, methods of manufacturing said solid dispersions, and methods of using said solid dispersions.

Provided are solid dispersions of Compound I having the formula:

##STR00001##

wherein Compound I is substantially amorphous, methods of manufacturing said solid dispersions, and methods of using said solid dispersions.

Eye drops containing cyclosporin A are prepared in the form of an emulsion, a microemulsion, or a lipophilic/hydrophilic micellar solution whose lipophilic, and hence oily, phase contains cyclosporin A. Preparation of the eye drops begins by eliminating at least 99 wt % of ethanol contained in an oily solution of cyclosporin A, under a flow of nitrogen under a pressure of 0.5 bar, at a temperature of from 2° C. to 45° C. and for a period of from 0.25 h to 24 h. The concentrate of cyclosporine is then diluted in an aqueous solution. Next, an emulsion, a microemulsion, or a micellar solution being 75% aqueous phase is created by stirring the concentrated cyclosporine A with the aqueous solution to mix them together. The resulting mixture is sterilely packaged as eye drops in packaging that is suitable for ophthalmic use.

Eye drops containing cyclosporin A are prepared in the form of an emulsion, a microemulsion, or a lipophilic/hydrophilic micellar solution whose lipophilic, and hence oily, phase contains cyclosporin A. Preparation of the eye drops begins by eliminating at least 99 wt % of ethanol contained in an oily solution of cyclosporin A, under a flow of nitrogen under a pressure of 0.5 bar, at a temperature of from 2° C. to 45° C. and for a period of from 0.25 h to 24 h. The concentrate of cyclosporine is then diluted in an aqueous solution. Next, an emulsion, a microemulsion, or a micellar solution being 75% aqueous phase is created by stirring the concentrated cyclosporine A with the aqueous solution to mix them together. The resulting mixture is sterilely packaged as eye drops in packaging that is suitable for ophthalmic use.

Novel antimicrobial compositions and kits thereof containing these antimicrobial compositions, methods of manufacture and methods of use thereof are disclosed. The novel aqueous transdermal or topical delivery systems are useful, inter alia, for treatment of various microbial infections, including for use on tissue infections, particularly skin antisepsis and/or nasal mucosal tissue antisepsis to a mammalian host in need thereof.

Novel antimicrobial compositions and kits thereof containing these antimicrobial compositions, methods of manufacture and methods of use thereof are disclosed. The novel aqueous transdermal or topical delivery systems are useful, inter alia, for treatment of various microbial infections, including for use on tissue infections, particularly skin antisepsis and/or nasal mucosal tissue antisepsis to a mammalian host in need thereof.

The invention provides a method of inducing satiety in a subject comprising a step of orally administering a composition comprising an effective amount of a first agent capable of inducing satiety and of a second agent capable of augmenting the satiety-inducing effect of the first agent. Also disclosed are compositions for carrying out the method, and a body weight management system comprising such compositions in combination with a device configured for the collection, storage and/or display of information relating to a subject's response to a predefined therapeutic regimen of orally administering the composition.

The invention provides a method of inducing satiety in a subject comprising a step of orally administering a composition comprising an effective amount of a first agent capable of inducing satiety and of a second agent capable of augmenting the satiety-inducing effect of the first agent. Also disclosed are compositions for carrying out the method, and a body weight management system comprising such compositions in combination with a device configured for the collection, storage and/or display of information relating to a subject's response to a predefined therapeutic regimen of orally administering the composition.

An applicator for medical-use liquids includes a handle having a hollow cylindrical member, a container incorporated in the cylindrical member, and a cleaving member of the container; and an applying section having an attachment plate of an application pad (integrally) fixed to a lower end of the cylindrical member to be an inclined cross section and the application pad fixed to the attachment plate. The attachment plate has a bank section formed thick at a peripheral edge, a base bottom section formed as a recess in a center, an inclined outflow hole opened inclinedly with respect to the base bottom section near the base bottom section center such that the solution flows out toward an attachment plate distal end direction, and a weir provided in an arcuate or crescent shape. A flow of the solution flowed out from the inclined outflow hole is reversed to flow backward by the weir.